Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. Transactions on Cancer
  4. Vol 6, Issue 1, 2025

Ferroptosis Induction and Cisplatin Chemoresistance Reversal by MASTL Inhibition in Ovarian Cancer

Download as PDF

DOI: 10.23977/tranc.2025.060106 | Downloads: 9 | Views: 162

Author(s)

Rong Yan 1, Yanting Gu 1

Affiliation(s)

1 Shenyang Pharmaceutical University, Shenyang, China

Corresponding Author

Yanting Gu

ABSTRACT

Ovarian cancer remains the leading cause of mortality among gynecologic malignancies, posing a significant threat to women’s health worldwide. Although cytoreductive surgery combined with platinum-based chemotherapy constitutes the standard treatment for epithelial ovarian cancer, therapeutic efficacy is markedly limited in patients with platinum-resistant recurrent disease. Microtubule-associated serine/threonine kinase-like (MASTL), a key regulator of mitotic progression, has recently garnered increasing attention due to its association with poor prognosis and chemotherapy resistance in various cancers. However, the precise role of MASTL deregulation in ovarian cancer progression and chemoresistance remains poorly understood. In this study, in vitro experiments demonstrated that MASTL is aberrantly overexpressed in ovarian cancer cells, particularly in cisplatin-resistant cell lines (CoC1/DDP). Genetic silencing of MASTL significantly sensitized resistant cells to cisplatin, induced apoptosis, and enhanced chemotherapy-induced cell death, potentially through the modulation of ferroptosis-related pathways. Further, treatment with a small-molecule MASTL inhibitor potentiated cisplatin-induced DNA damage and apoptosis in vitro. To our knowledge, this is the first study to demonstrate that pharmacological inhibition of MASTL enhances cisplatin sensitivity in ovarian cancer by ferroptosis. These findings suggest a promising therapeutic strategy targeting MASTL to overcome chemoresistance and improve clinical outcomes in patients with ovarian cancer.

KEYWORDS

Ovarian Cancer, MASTL, Cisplatin Resistance, Ferroptosis

CITE THIS PAPER

Rong Yan, Yanting Gu, Ferroptosis Induction and Cisplatin Chemoresistance Reversal by MASTL Inhibition in Ovarian Cancer. Transactions on Cancer (2025) Vol. 6: 34-43. DOI: http://dx.doi.org/10.23977/tranc.2025.060106.

REFERENCES

[1] Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., Nemunaitis, J.: Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci. 22, 6532 (2021). https://doi.org/10.3390/ijms22126532
[2] Mochida, S., Maslen, S.L., Skehel, M., Hunt, T.: Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science. 330, 1670–1673 (2010). https://doi.org/10.1126/science.1195689
[3] Gharbi-Ayachi, A., Labbé, J.-C., Burgess, A., Vigneron, S., Strub, J.-M., Brioudes, E., Van-Dorsselaer, A., Castro, A., Lorca, T.: The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science. 330, 1673–1677 (2010). https://doi.org/10.1126/science.1197048
[4] Kim, A.-Y., Yoon, Y.N., Leem, J., Lee, J.-Y., Jung, K.-Y., Kang, M., Ahn, J., Hwang, S.-G., Oh, J.S., Kim, J.-S.: MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer. Front. Oncol. 10, (2020). https://doi.org/10.3389/fonc.2020.571601
[5] Gouttia, O.G., Zhao, J., Li, Y., Zwiener, M.J., Wang, L., Oakley, G.G., Peng, A.: The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma. Front Cell Dev Biol. 10, 904719 (2022). https://doi. org/10.3389/fcell.2022.904719
[6] Fatima, I., Singh, A.B., Dhawan, P.: MASTL: A novel therapeutic target for Cancer Malignancy. Cancer Med. 9, 6322–6329 (2020). https://doi.org/10.1002/cam4.3141
[7] Guo, K., Lu, M., Bi, J., Yao, T., Gao, J., Ren, F., Zhu, L.: Ferroptosis: mechanism, immunotherapy and role in ovarian cancer. Front Immunol. 15, 1410018 (2024). https://doi.org/10.3389/fimmu.2024.1410018
[8] Vera, J., Lartigue, L., Vigneron, S., Gadea, G., Gire, V., Del Rio, M., Soubeyran, I., Chibon, F., Lorca, T., Castro, A.: Greatwall promotes cell transformation by hyperactivating AKT in human malignancies. Elife. 4, e10115 (2015). https: //doi.org/10.7554/eLife.10115
[9] Ocasio, C.A., Rajasekaran, M.B., Walker, S., Le Grand, D., Spencer, J., Pearl, F.M.G., Ward, S.E., Savic, V., Pearl, L.H., Hochegger, H., Oliver, A.W.: A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct. Oncotarget. 7, 71182–71197 (2016). https://doi. org/10. 18632/oncotarget.11511
[10] Uppada, S.B., Gowrikumar, S., Ahmad, R., Kumar, B., Szeglin, B., Chen, X., Smith, J.J., Batra, S.K., Singh, A.B., Dhawan, P.: MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling. Mol Cancer. 17, 111 (2018). https://doi.org/10.1186/s12943-018-0848-3
[11] Ch, H., Hc, H., Fs, S., Pw, W., Lx, Y., Db, S., Yc, W.: An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Theranostics. 11, (2021). https://doi.org/10. 7150/thno.57803
[12] Qian, B., Che, L., Du, Z.-B., Guo, N.-J., Wu, X.-M., Yang, L., Zheng, Z.-X., Gao, Y.-L., Wang, M.-Z., Chen, X.-X., Xu, L., Zhou, Z.-J., Lin, Y.-C., Lin, Z.-N.: Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling. Theranostics. 13, 4288–4302 (2023). https://doi.org/10.7150/thno.82132

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 1072
Visits: 75181

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.